Telisotuzumab vedotin
Telisotuzumab vedotin (pronunciation: te-lis-o-tu-zu-mab ve-do-tin) is a monoclonal antibody-drug conjugate used in the treatment of certain types of cancer.
Etymology
The name "Telisotuzumab vedotin" is derived from the components of the drug. "Teliso" is a prefix used in the naming of monoclonal antibodies, "tuzumab" indicates that the drug targets tumor cells, and "vedotin" refers to the cytotoxic drug that is attached to the antibody.
Mechanism of Action
Telisotuzumab vedotin works by binding to the c-Met receptor on the surface of cancer cells. The drug is then internalized by the cell, where the cytotoxic agent vedotin is released, causing cell death.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Drug conjugate: A type of drug that combines a cytotoxic (cell-killing) agent with a specific targeting molecule.
- c-Met: A protein that in humans is encoded by the MET gene. It has been found to be overexpressed in many types of tumors.
See Also
External links
- Medical encyclopedia article on Telisotuzumab vedotin
- Wikipedia's article - Telisotuzumab vedotin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski